260 related articles for article (PubMed ID: 32332430)
1. Homozygous familial hypercholesterolemia: what treatments are on the horizon?
Bajaj A; Cuchel M
Curr Opin Lipidol; 2020 Jun; 31(3):119-124. PubMed ID: 32332430
[TBL] [Abstract][Full Text] [Related]
2. Advancements in the Treatment of Homozygous Familial Hypercholesterolemia.
Bajaj A; Cuchel M
J Atheroscler Thromb; 2022 Aug; 29(8):1125-1135. PubMed ID: 35466160
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors.
Pirillo A; Catapano AL; Norata GD
Curr Atheroscler Rep; 2021 Oct; 23(12):79. PubMed ID: 34698927
[TBL] [Abstract][Full Text] [Related]
4. Novel therapies for familial hypercholesterolemia.
Mohamed F; Seedat F; Raal FJ
Curr Opin Endocrinol Diabetes Obes; 2021 Apr; 28(2):188-195. PubMed ID: 33278127
[TBL] [Abstract][Full Text] [Related]
5. Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies.
Raal FJ; Hegele RA; Ruzza A; López JAG; Bhatia AK; Wu J; Wang H; Gaudet D; Wiegman A; Wang J; Santos RD
Arterioscler Thromb Vasc Biol; 2024 May; 44(5):1156-1164. PubMed ID: 38545781
[TBL] [Abstract][Full Text] [Related]
6. Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab.
Thedrez A; Blom DJ; Ramin-Mangata S; Blanchard V; Croyal M; Chemello K; Nativel B; Pichelin M; Cariou B; Bourane S; Tang L; Farnier M; Raal FJ; Lambert G
Arterioscler Thromb Vasc Biol; 2018 Mar; 38(3):592-598. PubMed ID: 29284604
[TBL] [Abstract][Full Text] [Related]
7. Contemporary lipid-lowering management and risk of cardiovascular events in homozygous familial hypercholesterolaemia: insights from the Italian LIPIGEN Registry.
D'Erasmo L; Bini S; Casula M; Gazzotti M; Bertolini S; Calandra S; Tarugi P; Averna M; Iannuzzo G; Fortunato G; Catapano AL; Arca M;
Eur J Prev Cardiol; 2024 Jun; 31(8):1038-1047. PubMed ID: 38374534
[TBL] [Abstract][Full Text] [Related]
8. A Review of Progress on Targeting LDL Receptor-Dependent and -Independent Pathways for the Treatment of Hypercholesterolemia, a Major Risk Factor of ASCVD.
Srivastava RAK
Cells; 2023 Jun; 12(12):. PubMed ID: 37371118
[TBL] [Abstract][Full Text] [Related]
9. Evinacumab: Mechanism of action, clinical, and translational science.
Dingman R; Bihorel S; Gusarova V; Mendell J; Pordy R
Clin Transl Sci; 2024 Jun; 17(6):e13836. PubMed ID: 38845393
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of Gemcabene in Homozygous Familial Hypercholesterolemia (from COBALT-1).
Gaudet D; Durst R; Lepor N; Bakker-Arkema R; Bisgaier C; Masson L; Golden L; Kastelein JJ; Hegele RA; Stein E
Am J Cardiol; 2019 Dec; 124(12):1876-1880. PubMed ID: 31685212
[TBL] [Abstract][Full Text] [Related]
11. Evinacumab-dgnb (Evkeeza-REGN1500), A Novel Lipid-Lowering Therapy for Homozygous Familial Hypercholesterolemia.
White RT; Sankey KH; Nawarskas JJ
Cardiol Rev; 2024 Mar-Apr 01; 32(2):180-185. PubMed ID: 37071085
[TBL] [Abstract][Full Text] [Related]
12. How Genetic Variants in Children with Familial Hypercholesterolemia Not Only Guide Detection, but Also Treatment.
van den Bosch SE; Corpeleijn WE; Hutten BA; Wiegman A
Genes (Basel); 2023 Mar; 14(3):. PubMed ID: 36980941
[TBL] [Abstract][Full Text] [Related]
13. Lessons learned from the evinacumab trials in the treatment of homozygous familial hypercholesterolemia.
Khoury E; Croteau L; Lauzière A; Gaudet D
Future Cardiol; 2022 Jun; 18(6):507-518. PubMed ID: 35469449
[TBL] [Abstract][Full Text] [Related]
14. New clinical perspectives of hypolipidemic drug therapy in severe hypercholesterolemia.
Stefanutti C; Morozzi C; Di Giacomo S
Curr Med Chem; 2012; 19(28):4861-8. PubMed ID: 22963620
[TBL] [Abstract][Full Text] [Related]
15. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
16. Evinacumab for Homozygous Familial Hypercholesterolemia.
Raal FJ; Rosenson RS; Reeskamp LF; Hovingh GK; Kastelein JJP; Rubba P; Ali S; Banerjee P; Chan KC; Gipe DA; Khilla N; Pordy R; Weinreich DM; Yancopoulos GD; Zhang Y; Gaudet D;
N Engl J Med; 2020 Aug; 383(8):711-720. PubMed ID: 32813947
[TBL] [Abstract][Full Text] [Related]
17. Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia.
Wiegman A; Greber-Platzer S; Ali S; Reijman MD; Brinton EA; Charng MJ; Srinivasan S; Baker-Smith C; Baum S; Brothers JA; Hartz J; Moriarty PM; Mendell J; Bihorel S; Banerjee P; George RT; Hirshberg B; Pordy R
Circulation; 2024 Jan; 149(5):343-353. PubMed ID: 37860863
[TBL] [Abstract][Full Text] [Related]
18. Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia.
Tomlinson B; Patil NG; Fok M; Lam CWK
Endocrinol Metab (Seoul); 2021 Apr; 36(2):279-295. PubMed ID: 33866776
[TBL] [Abstract][Full Text] [Related]
19. Drugs that Mimic the Effect of Gene Mutations for the Prevention or the Treatment of Atherosclerotic Disease: From PCSK9 Inhibition to ANGPTL3 Inactivation.
Athyros VG; Katsiki N; Dimakopoulou A; Patoulias D; Alataki S; Doumas M
Curr Pharm Des; 2018; 24(31):3638-3646. PubMed ID: 30306859
[TBL] [Abstract][Full Text] [Related]
20. Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity.
Banerjee P; Chan KC; Tarabocchia M; Benito-Vicente A; Alves AC; Uribe KB; Bourbon M; Skiba PJ; Pordy R; Gipe DA; Gaudet D; Martin C
Arterioscler Thromb Vasc Biol; 2019 Nov; 39(11):2248-2260. PubMed ID: 31578082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]